CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Lonza Group AG Company Snapshot
Lonza Group AG operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other pharmaceutical manufacturers in Europe: UCB Sa of Belgium (2018 sales of 4.63 billion Euro [US$5.10 billion] of which 31% was Cimzia), H. Lundbeck A/S of Denmark (18.12 billion Danish Kroner [US$2.67 billion] of which 100% was Pharmaceuticals), and Protek PAO which is based in Russia (251.73 billion Russian Rubles [US$3.84 billion] of which 72% was Distribution).

Sales Analysis. During the year ended December of 2018, sales at Lonza Group AG were 5.54 billion Swiss Francs (US$5.58 billion). This is an increase of 8.6% versus 2017, when the company's sales were 5.11 billion Swiss Francs. This was the fifth consecutive year of sales increases at Lonza Group AG (and since 2013, sales have increased a total of 55%). Sales of Pharma&biotech saw an increase that was more than double the company's growth rate: sales were up 46.6% in 2018, from 2.12 billion Swiss Francs to 3.11 billion Swiss Francs. Not all segments of Lonza Group AG experienced an increase in sales in 2018: sales of Specialty Ingredients fell 0.4% to 2.39 billion Swiss Francs.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Lonza Group AG
  Stock Performance Chart for Lonza Group AG
 
  Stock Data: Recent Stock Performance:
  Current Price (9/6/2019): 358.30
(Figures in Swiss Francs)
1 Week 2.4%   13 Weeks 3.7%  
4 Weeks 11.5%   52 Weeks 15.7%  
 
Lonza Group AG Key Data:
  Ticker: LONN Country: Switzerland
  Exchanges: FRA GVA OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2018 Sales 5,542,000,000
(Year Ending Jan 2019).
Employees: 15,375
  Currency: Swiss Francs Market Cap: 26,522,642,265
  Fiscal Yr Ends: December Shares Outstanding: 74,023,562
  Share Type: Namenaktie Closely Held Shares: 107,572
 
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.